Bioaffinity Technologies

bioAffinity Technologies, based in San Antonio, TX, is a pioneering biotechnology company specializing in early cancer detection and therapeutic advancements. Their innovative CyPath Lung test utilizes advanced flow cytometry technology to detect early-stage lung cancer non-invasively, offering a crucial tool for physicians in managing high-risk patients.

Additionally, bioAffinity Technologies' subsidiary, OncoSelect Therapeutics, focuses on developing cancer therapeutics that selectively target and kill cancer cells while sparing normal tissue. Their research on porphyrins has led to promising discoveries in cancer treatment, with ongoing efforts to advance these novel therapies through preclinical studies.

Generated from the website